Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Surmodics jumps amid pre-trial hearing in FTC′s suit to block sale to GTCR (SeekingAlpha) +++ SURMODICS Aktie +6,25%

IMUNON Aktie

 >IMUNON Aktienkurs 
0.428 EUR    (Tradegate)
Ask: 0.438 EUR / 0 Stück
Bid: 0.418 EUR / 0 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 8 bis 22 Uhr!
IMUNON Aktie über LYNX handeln
>IMUNON Performance
1 Woche: -11,6%
1 Monat: -40,6%
3 Monate: -44,4%
6 Monate: -53,7%
1 Jahr: -61,8%
laufendes Jahr: -44,4%
>IMUNON Aktie
Name:  IMUNON INC. DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US15117N6022 / A3DWEJ
Symbol/ Ticker:  CBO (Frankfurt) / IMNN (NASDAQ)
Kürzel:  FRA:CBO, ETR:CBO, CBO:GR, NASDAQ:IMNN
Index:  -
Webseite:  https://imunon.com/
Marktkapitalisierung:  -
Umsatz:  -
EBITDA:  -
Gewinn je Aktie:  -
Schulden:  -
Liquide Mittel:  -
Umsatz-/ Gewinnwachstum:  - / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  - / 1.51 / -
Gewinnm./ Eigenkapitalr.:  - / -148.12%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  IMUNON
Letzte Datenerhebung:  26.07.25
>IMUNON Eigentümer
Aktien: -
f.h. Aktien: 12.87 Mio. St.
Insider Eigner: 9.37%
Instit. Eigner: 2.35%
>IMUNON Peer Group

 
24.07.25 - 20:01
XFRA: Deletion of Instruments from Boerse Frankfurt - 24.07.2025 (XETRA)
 
The following instruments on Boerse Frankfurt do have their last trading day on 24.07.2025 Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.07.2025 ISIN Name DE000A1R0RZ5 EKOSEM-AGRAR AG 12/27 DK0060036564 SPAR NORD BANK NAM. DK 10 US15117N6022 IMUNON INC. DL-,01 US92511W1080 VERRICA PHARMAC. DL-,0001 XS1813504666 SIGMA HOLDCO 18/26 REGS XS1827819910 SON.ESP.F.2 18/37 A1 XS1827820256 SON.ESP.F.2 18/37 A2 XS1917880871 SON.ESP.F.2 18/37 A3 XS1917881259 SON.ESP.F.2 18/37 A4 XS2198191962 TK ELEV. HOL REGS 20/28...
24.07.25 - 18:06
XFRA: ISIN Change (XETRA)
 
Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen US15117N6022 Imunon Inc. 24.07.2025 US15117N7012 Imunon Inc. 25.07.2025 Tausch 15:1 US92511W1080 Verrica Pharmaceuticals Inc. 24.07.2025 US92511W2070 Verrica Pharmaceuticals Inc. 25.07.2025 Tausch 10:1...
23.07.25 - 14:12
IMUNON announces reverse stock split (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
15.07.25 - 15:57
IMUNON granted Nasdaq extension to execute compliance plan (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
15.07.25 - 14:09
IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan (GlobeNewswire EN)
 
Management provides Nasdaq Hearing Panel with a comprehensive executable plan for long term compliance...
18.06.25 - 14:09
IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025 (GlobeNewswire EN)
 
ASCO 2025 overall survival data bolster IMNN-001's potential in advanced ovarian cancer, supported by robust translational results at ESMO...
17.06.25 - 14:09
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™ (GlobeNewswire EN)
 
Clinical Data Highlight PlaCCine's Six-Month Durability, Temperature Stability, and Manufacturing Advantages Over mRNA Vaccines...
03.06.25 - 14:06
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study (GlobeNewswire EN)
 
Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001's Ability to Recruit a Powerful Anti-Cancer Immune Response ...
02.06.25 - 14:09
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS (GlobeNewswire EN)
 
Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology...
28.05.25 - 23:18
IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire EN)
 
$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants...
27.05.25 - 14:09
IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025 (GlobeNewswire EN)
 
Presentation at ESMO will follow oral 2025 ASCO Annual Meeting presentation highlighting unprecedented survival data from Phase 2 OVATION 2 Study of IMNN-001...
26.05.25 - 07:48
IMUNON launches up to $9.75M securities offering (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
24.05.25 - 01:03
IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire EN)
 
$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants...
23.05.25 - 14:06
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer (GlobeNewswire EN)
 
Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group...
22.05.25 - 23:24
IMUNON Announces Withdrawal of Form S-1 Registration Statement (GlobeNewswire EN)
 
LAWRENCEVILLE, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (SEC) of the Company's Registration Statement on Form S-1 (No. 333-286403), as amended, originally filed on April 4, 2025 (Registration Statement), as the Company no longer intends to pursue a public offering under the Registration Statement at this time. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement....
15.05.25 - 14:09
IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19 (GlobeNewswire EN)
 
Company's PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines...
12.05.25 - 19:03
Imunon outlines 40% trial cost reduction and early readout potential as OVATION 3 Phase III launches (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.05.25 - 14:06
Imunon GAAP EPS of -$0.28 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.05.25 - 14:03
IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire EN)
 
First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer...
08.05.25 - 14:09
IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer (GlobeNewswire EN)
 
Company currently initiating additional trial sites and working with study investigators to enroll participants...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der Herr wird denen entgegenkommen, die verstehen, in den Tag hinein zu leben, immer ihre Pflicht tun, mit Ruhe, Würde und Geduld, ohne sich den Kopf heiß zu machen wegen der Dinge, die morgen oder in Zukunft geschehen können. - Papst Johannes XXIII.
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!